title: Dilemma: Correlation Between Serum Level of Hepcidin and IL-6 in Anemic Myeloma Patients.
abstract: BACKGROUND
  Anemia occurs in 60% to 80 % of patients with newly diagnosed myeloma multiplex (MM). The cause of anemia in MM is probably multi factorial and involved among the others hepcidin and some cytokines, especially interleukine-6. Anemia in MM is one of the risk factor used in Durie-Salmon classification for staging and prognostic score. Treatment options are set according to this score with most significant impact on survival.
  
  
  OBJECTIVE
  To estimate baseline level of serum hepcidin, IL-6 and iron metabolism markers in anemic MM patients, possible role of hepcidin and its interaction with IL-6.
  
  
  METHODS
  27 patients with newly diagnosed MM were enrolled in this observational, prospective study and age, gender matched 60 healthy controls. Erythrocyte count, hemoglobin, serum hepcidin, interleukin-6, iron, ferritin and transferrin were measured.
  
  
  RESULTS
  Anemia was diagnosed in 70% of MM patients. Serum hepcidin was significantly higher in MM group (55.5 ng/mL) than in control 5.9 ng/mL (p=0000). In myeloma patients serum IL-6 was 3.59 pg/mL, anemic 3.80 pg/mL, non-anemic 0.33 pg/mL, without significant difference. It was not found significant correlation between hepcidin and IL-6 in anemic myeloma patients.
  
  
  CONCLUSIONS
  High level of hepcidin probably causes anemia in MM but its high expression is not due only to IL-6.
authors.affiliation: Clinical center of Sarajevo University, Sarajevo, Bosnia and Herzegovina.
authors.forename: Lejla
authors.initials: L
authors.lastname: Ibricevic-Balic
authors.affiliation: Faculty of medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
authors.forename: Emina
authors.initials: E
authors.lastname: Icindic-Nakas
authors.affiliation: Faculty of medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
authors.forename: Sabaheta
authors.initials: S
authors.lastname: Hasic
authors.affiliation: Faculty of medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
authors.forename: Emina
authors.initials: E
authors.lastname: Kiseljakovic
authors.affiliation: Clinical center of Sarajevo University, Sarajevo, Bosnia and Herzegovina.
authors.forename: Alma
authors.initials: A
authors.lastname: Sofo-Hafizovic
authors.affiliation: Clinical center of Sarajevo University, Sarajevo, Bosnia and Herzegovina.
authors.forename: Sefkija
authors.initials: S
authors.lastname: Balic
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000097:blood / Q000175:diagnosis* / Q000209:etiology*; D000890:Anti-Infective Agents / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D005260:Female; D005293:Ferritins / Q000097:blood; D006454:Hemoglobins / Q000378:metabolism; D064451:Hepcidins / Q000097:blood*; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D007501:Iron / Q000097:blood; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications*; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D014168:Transferrin / Q000378:metabolism
chemical_list: D000890:Anti-Infective Agents; D015415:Biomarkers; D006454:Hemoglobins; D064451:Hepcidins; D015850:Interleukin-6; D014168:Transferrin; D005293:Ferritins; D007501:Iron
keywords: anemia; hepcidin; interleukin-6; multiple myeloma